{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-009510","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.057421+00:00","generated_at":"2026-05-17T14:04:10.810528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics reports Q2 net loss of $10.9M; Phase 3 LEVEL study enrollment on track for H1 2026","bullets":["Net loss of $10.9M in Q2 2025 vs $3.6M in Q2 2024; R&D spend $6.1M, G&A $5.7M.","Cash and equivalents of $105.5M as of June 30, 2025, expected to fund operations through 2027.","Phase 3 LEVEL study (TNX-103) enrollment target of 230 patients; completion expected H1 2026, topline data H2 2026.","On track to initiate second Phase 3 study, LEVEL-2, in 2025 with over 85 sites in 15 countries qualified.","Canadian patent allowed for TNX-103/102/101 and metabolites in PH-HFpEF, extending protection to 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-009510","json":"https://secwatch.observer/filing/0001654954-25-009510.json","markdown":"https://secwatch.observer/filing/0001654954-25-009510.md","text":"https://secwatch.observer/filing/0001654954-25-009510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425009510/0001654954-25-009510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425009510/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:04:10.810528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}